Follow the Claude Bernard Award feature to see what are the differences and potential between GIP and GLP-1? I EASD 2022

*For medical professionals only

Therapeutic potential for type 2 diabetes

The action of receptor agonists (GLP-1RA).

GLP-1 receptors and other receptors

Co-agonists (such as GIP).

Finally, Professor Michael A.

GLP-1 receptor agonists are insulin-based hypoglycemic drugs with the following characteristics:

• Despite stimulating insulin secretion, the risk of hypoglycemia is small;

• The hypoglycemic effect on type 2 diabetes is similar to or even better than basal insulin;

• Weight loss by reducing food intake;

• Reducing the risk of cardiovascular events in people at high cardiovascular risk;

• There are gastrointestinal reactions, but there are no serious adverse effects, such as tumors
  .
  
  

The latest advances are synagonists for GLP-1 receptors and other receptors (such as GIP), which benefit blood sugar control and weight loss, but there are still many questions to be answered
about the therapeutic potential of GIP receptor agonists.

Reference source: